8551 Results for "

binding

" in MedChemExpress (MCE) Product Catalog:
Products (8551)

8551 Results for "binding" in MCE Product Catalog:

19
19 Cited Publications
Cat. No.: HY-10528
CAS No.: 254964-60-8
Purity:  99.94%
Synonyms: ABR-215050
Target:  

HDAC

Research Areas:  

Cancer

Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn 2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-100689
CAS No.: 263717-53-9
Purity:  99.11%
Synonyms: PPT
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-19831
CAS No.: 315706-13-9
4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-13928
CAS No.: 317318-84-6
Purity:  99.94%
Synonyms: GW610742
GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-148439
CAS No.: 2765081-21-6
Purity:  99.68%
Synonyms: RMC-6236; RAS-IN-2
Target:  

Ras PERK

Research Areas:  

Cancer

Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299
CAS No.: 283609-79-0
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299A
CAS No.: 2828433-17-4
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-N0629
CAS No.: 4373-41-5
Synonyms: Crategolic acid; 2α-Hydroxyoleanolic acid
Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-13955
CAS No.: 144701-48-4
Purity:  99.79%
Synonyms: BIBR 277
Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-15778A
CAS No.: 306288-04-0
Purity:  99.22%
AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [ 125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-136175
CAS No.: 2169919-21-3
Purity:  99.76%
Synonyms: SNDX-5613
Research Areas:  

Cancer

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-102084
CAS No.: 1239600-18-0
Purity:  98.93%
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130 .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-104040
CAS No.: 1338934-59-0
Purity:  99.95%
Synonyms: Orin1001
Target:  

IRE1

Research Areas:  

Cancer

MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-10389
CAS No.: 467214-20-6
Purity:  99.59%
Synonyms: 17-DMAG; KOS-1022; NSC 707545
Target:  

HSP

Research Areas:  

Cancer

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 nM.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-16060
CAS No.: 956104-40-8
Synonyms: ARN-509
Target:  

Androgen Receptor

Research Areas:  

Cancer

Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-A0005
CAS No.: 123318-82-1
Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-12024
CAS No.: 467214-21-7
Purity:  98.80%
Synonyms: 17-DMAG hydrochloride; KOS-1022 hydrochloride; BMS 826476
Target:  

HSP Apoptosis

Research Areas:  

Cancer

Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-B1286
CAS No.: 59703-84-3
Synonyms: Sodium piperacillin
Piperacillin sodium is a semisynthetic broad-spectrum β-lactam antibiotic which exhibits potent bactericidal activity against Gram-negative bacteria as well as select Gram-positive strains through penicillin-binding proteins. Piperacillin is most commonly used in combination with the β-lactamase inhibitor Tazobactam .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-B1923
CAS No.: 61477-96-1
Synonyms: Pipracil
Piperacillin is a semisynthetic broad-spectrum β-lactam antibiotic which exhibits potent bactericidal activity against Gram-negative bacteria as well as select Gram-positive strains through penicillin-binding proteins. Piperacillin is most commonly used in combination with the β-lactamase inhibitor Tazobactam .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-108847
CAS No.: 185243-69-0
Purity:  99.20%

Target:  

TNF Receptor Bacterial

Research Areas:  

Inflammation/Immunology Cancer

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
loading...
    loading...